thalidomide · Bristol-Myers · NDA 020785
Thalomid
Earliest generic entry, as listed · earliest of 4 marketed strengths
Open now
No unexpired patents or exclusivities are listed for this product.
Listed patents · 0 unexpired
No unexpired patents listed.
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
- First generic approved · ANDA 213267, Natco · 020785-001Approved 24 Apr 2026Detected 25 Oct 2026Historical import
- Generic approved · ANDA 213267, Natco · 020785-001Approved 24 Apr 2026Detected 25 Oct 2026Historical import
Products covered · 4
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 020785 · 001 · RLD | capsule, oral | 50MG | open |
| 020785 · 002 · RLD | capsule, oral | 100MG | open |
| 020785 · 003 · RLD | capsule, oral | 200MG | open |
| 020785 · 004 · RLD | capsule, oral | 150MG | open |